ºñ´¢»ý½Ä±â Ä¡·áÁ¦ ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2024-2032³â)
Genitourinary Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
»óǰÄÚµå : 1616250
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 215 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ºñ´¢»ý½Ä±â Ä¡·á ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 287¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â 2.3%ÀÇ CAGRÀ» ±â·ÏÇÕ´Ï´Ù.

Çõ½ÅÀûÀΠȣ¸£¸ó ¿ä¹ýÀº º¸´Ù È¿°úÀûÀÌ°í ¾ÈÀüÇÑ ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á »ê¾÷ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Á¾¾çÇÐ, ƯÈ÷ Àü¸³¼±¾Ï Ä¡·áÀÇ ÃÖ±Ù ¹ßÀüÀº ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 3¿ù ºê¸®½ºÅç ¸¶À̾ ½ºÄûºê(Bristol Myers Squibb)´Â ÀýÁ¦ ºÒ°¡´ÉÇÑ ¶Ç´Â ÀüÀ̼º ¿ä·Î»óÇǾÏ(UC) ¼ºÀΠȯÀÚÀÇ 1Â÷ Ä¡·áÁ¦·Î ¿Éµðº¸(´Ïº¼·ç¸¿)¿Í ½Ã½ºÇÃ¶óÆ¾ ¹× Áª½ÃŸºóÀÇ º´¿ë¿ä¹ýÀÌ FDAÀÇ ½ÂÀÎÀ» ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. À̹ø ½ÂÀÎÀ¸·Î ȸ»çÀÇ °æÀï·Â°ú ½ÃÀå µµ´Þ ¹üÀ§°¡ ´õ¿í °­È­µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

½ÃÀåÀº ¾à¹° À¯Çü¿¡ µû¶ó È£¸£¸ó ¿ä¹ý, Ç׿°Áõ¾à, ±âŸ ¾à¹°·Î ³ª´¹´Ï´Ù. È£¸£¸ó ¿ä¹ýÀº ÁøÇ༺ Àü¸³¼±¾ÏÀÇ ÁÖ¿ä Ä¡·á¹ýÀ̸ç, Á¾Á¾ ¾Èµå·Î°Õ Á¦°Å ¿ä¹ý(ADT)À» »ç¿ëÇÏ¿© Å×½ºÅ佺Å×·Ð ¼öÄ¡¸¦ ³·Ãß´Â µ¥ »ç¿ëµË´Ï´Ù. Àü ¼¼°è¿¡¼­ Àü¸³¼±¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È£¸£¸ó ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Åõ¿© Ƚ¼ö°¡ ÀûÀº Àå±â ÀÛ¿ëÇü µðÆ÷ Á¦Á¦´Â ȯÀÚÀÇ ¼øÀÀµµ¿Í Ä¡·á °á°ú¸¦ °³¼±ÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.

¼¼°è Àα¸ÀÇ °í·ÉÈ­·Î ÀÎÇØ Àü¸³¼±¾Ï, Àü¸³¼±ºñ´ëÁõ(BPH) µî È£¸£¸ó °ü·Ã ºñ´¢»ý½Ä±â ÁúȯÀ» °ü¸®Çϱâ À§ÇÑ È£¸£¸ó ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿ëµµº°·Î´Â ¿ä·Î°¨¿°(UTI) ºÎ¹®ÀÌ 2023³â 31% ÀÌ»ó ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °øÁߺ¸°Ç Ä·ÆäÀÎÀ¸·Î ÀÎÇØ ¿ä·Î°¨¿°ÁõÀÇ Áõ»ó°ú ÇÕº´Áõ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Áø´ÜÀ²ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¶±â Áø´Ü°ú Ä¡·á°¡ ¸Å¿ì Áß¿äÇϸç, ÀÌ´Â ¿ä·Î°¨¿° Ä¡·á ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº ȯÀÚµéÀÌ ¿ä·Î°á¼®ÀÌ Àç¹ßÇϹǷΠ¹Ýº¹ÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇÕ´Ï´Ù.

½ÃÀå ¹üÀ§
°³½Ã³â 2023³â
¿¹Ãø³â 2024-2032³â
°³½Ã °¡°Ý 287¾ï ´Þ·¯
¿¹»ó °¡°Ý 349¾ï ´Þ·¯
CAGR 2.3%

ÀÌ·¯ÇÑ ³ôÀº Àç¹ß·üÀº Àå±âÀûÀÌ°í ¿¹¹æÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì ºñ´¢»ý½Ä±â Ä¡·á ½ÃÀåÀº ¿¬Æò±Õ 2.1%ÀÇ ¼ºÀå·üÀ» º¸À̸ç 2032³â 154¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦¾à »ê¾÷ÀÇ Áß¿äÇÑ ºÎ¹®ÀÎ ¹Ì±¹ ½ÃÀåÀº ºñ´¢»ý½Ä±â ÁúȯÀÇ ³ôÀº À¯º´·ü, ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, Áö¼ÓÀûÀÎ ¿¬±¸°³¹ßÀÌ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ºñ¸¸°ú ´ç´¢º´°ú °°Àº »ýȰ½À°üº´ Áõ°¡´Â ºñ´¢»ý½Ä±â Áúȯ Áõ°¡·Î À̾îÁ® ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÇ ±ÔÁ¦ ½ÂÀÎÀº ½ÃÀå ȯ°æ Çü¼º¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ½Å¾à ½ÂÀÎÀ¸·Î Ä¡·á ¿É¼ÇÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¾àÁ¦ À¯Çüº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¿ëµµº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : À¯Åë ä³Îº°, 2021-2032³â

Á¦9Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦10Àå ±â¾÷ °³¿ä

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Genitourinary Drugs market size reached USD 28.7 billion in 2023 and will record 2.3% CAGR between 2024 and 2032. Innovative hormonal therapies are driving industry growth by offering more effective and safer options. Recent advancements in oncology, particularly in prostate cancer therapeutics, are significantly impacting the market. For instance, in March 2024, Bristol Myers Squibb announced FDA approval for Opdivo (nivolumab) combined with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC). This approval is set to enhance the company's competitive position and market reach.

The market is segmented by drug type into hormonal therapy, anti-infectives, and other drug types. Hormonal therapy serves as a primary treatment for advanced prostate cancer, often utilizing androgen deprivation therapy (ADT) to lower testosterone levels. The global rise in prostate cancer incidence is increasing the demand for hormonal therapies. Long-acting depot formulations, which require less frequent dosing, improve patient compliance and treatment outcomes, further driving market growth.

The aging global population is also raising the demand for hormonal therapies to manage hormone-related genitourinary disorders such as prostate cancer and benign prostatic hyperplasia (BPH). In terms of applications, the urinary tract infections (UTIs) segment held over 31% market share in 2023. Public health campaigns have increased awareness of UTI symptoms and complications, leading to higher diagnosis rates. Early diagnosis and treatment are crucial, boosting the demand for UTI medications and driving market growth. Many patients experience recurrent UTIs, necessitating repeated treatments.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$28.7 Billion
Forecast Value$34.9 Billion
CAGR2.3%

This high recurrence rate fuels the demand for long-term and prophylactic therapies, contributing to market growth. North America genitourinary drugs market is projected to grow at a CAGR of 2.1%, reaching USD 15.4 billion by 2032. The U.S. market, a significant segment of the pharmaceutical industry, is driven by a high prevalence of genitourinary disorders, advanced healthcare infrastructure, and ongoing research and development. The increasing incidence of lifestyle-related disorders such as obesity and diabetes is linked to a rise in genitourinary conditions, further fueling market growth. Regulatory approvals by the U.S. Food and Drug Administration (FDA) play a crucial role in shaping the market landscape, with new drug approvals expanding treatment options.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Route of administration, 2021 - 2032 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

Chapter 10 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â